These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 26077360)
1. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents. Sekeres MA Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360 [TBL] [Abstract][Full Text] [Related]
2. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Estey EH Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301 [TBL] [Abstract][Full Text] [Related]
3. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes. Tohyama K Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698 [TBL] [Abstract][Full Text] [Related]
4. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]. Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776 [No Abstract] [Full Text] [Related]
5. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy? Lowder JN; Taverna P; Issa JP Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345 [No Abstract] [Full Text] [Related]
6. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Xie M; Jiang Q; Xie Y Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977 [TBL] [Abstract][Full Text] [Related]
7. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011 [TBL] [Abstract][Full Text] [Related]
8. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156 [TBL] [Abstract][Full Text] [Related]
9. The euphoria of hypomethylating agents in MDS and AML: is it justified? Sekeres MA Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530 [TBL] [Abstract][Full Text] [Related]
10. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940 [TBL] [Abstract][Full Text] [Related]
11. [Hypomethylating agents for the treatment of myelodysplastic syndromes]. Itzykson R; Fenaux P Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482 [TBL] [Abstract][Full Text] [Related]
12. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA; Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847 [TBL] [Abstract][Full Text] [Related]
13. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
14. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405 [TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795 [TBL] [Abstract][Full Text] [Related]
16. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Lübbert M Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943 [No Abstract] [Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Joeckel TE; Lübbert M Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063 [TBL] [Abstract][Full Text] [Related]
18. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice. Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373 [TBL] [Abstract][Full Text] [Related]
19. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Roberts DA; Steensma DP Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome. Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Lee WS; Joo YD Eur J Haematol; 2015 Jun; 94(6):546-53. PubMed ID: 25315896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]